Today: 31 January 2026
Subscribe
Browse Category

NASDAQ:ALNY News 20 December 2025 - 13 January 2026

Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus

Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus

New York, January 13, 2026, 14:47 ET — During regular trading hours Shares of Alnylam Pharmaceuticals slipped 0.1% to $370.39 in Tuesday afternoon trading, as investors weighed the company’s updated sales forecast alongside its new five-year strategy. Based in Cambridge, Massachusetts, the company revealed preliminary 2025 sales and 2026 guidance in a Form 8-K tied to its “Alnylam 2030” plan.…
13 January 2026
·····
Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY

Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY

New York, Jan 12, 2026, 20:02 EST — Market closed Alnylam Pharmaceuticals’ shares fell sharply on Monday after the drugmaker’s preliminary fourth-quarter sales for its flagship heart drug Amvuttra came in below Wall Street expectations. The decline hit as investors digested the company’s new five-year strategy and 2026 revenue outlook, rolled out around the J.P. Morgan Healthcare Conference in San…
13 January 2026
·····
Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

New York, Jan 12, 2026, 16:34 (EST) — After-hours Alnylam Pharmaceuticals shares dropped in late Monday trading after the RNA interference drugmaker unveiled a new five-year plan and provided early 2026 sales guidance, along with preliminary figures for 2025. The stock slipped roughly 6.7% to $370.91. The company unveiled its “Alnylam 2030” initiative, aiming for “leadership in ATTR amyloidosis” and…
12 January 2026
·····
Alnylam Pharmaceuticals (ALNY) Stock After Hours: Nasdaq-100 debut, fresh catalysts, and what to watch before Tuesday’s open (Dec. 23)

Alnylam Pharmaceuticals (ALNY) Stock After Hours: Nasdaq-100 debut, fresh catalysts, and what to watch before Tuesday’s open (Dec. 23)

Dec. 22, 2025 — After the closing bell, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is finishing the day in the spotlight for a reason that has nothing to do with a clinical readout—at least not directly. Monday marked the company’s first trading day as a Nasdaq-100 constituent, a mechanical event that can reshape near-term flows even when the underlying business story…
23 December 2025
·····
Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook

Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook

Dec. 22, 2025 — Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) is stepping into a new tier of market visibility today as its Nasdaq-100 Index membership takes effect ahead of the opening bell—an index catalyst that can influence near-term trading and broaden long-term institutional ownership. Nasdaq ALNY was trading around $405.60 on Dec. 22 (time-stamped 16:37 UTC), up about 1.3% versus the…
22 December 2025
·····
Alnylam Pharmaceuticals (ALNY) Stock: Nasdaq-100 Entry, Amvuttra Momentum, Analyst Targets and Key Risks to Know Before the Dec. 22, 2025 Market Open

Alnylam Pharmaceuticals (ALNY) Stock: Nasdaq-100 Entry, Amvuttra Momentum, Analyst Targets and Key Risks to Know Before the Dec. 22, 2025 Market Open

Ahead of the U.S. stock market open on Monday, December 22, 2025, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is stepping into a new spotlight—not just for biotech fundamentals, but also for a major index catalyst that can reshape short-term trading dynamics. As of the most recent close, ALNY last traded around $400.23, within a roughly $220–$500 52-week range. Below is what…
22 December 2025
·····
Alnylam Pharmaceuticals (ALNY) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025

Alnylam Pharmaceuticals (ALNY) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025

As of Saturday, December 20, 2025, investors are digesting a busy stretch of developments around Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)—from Nasdaq-100 index inclusion (effective Dec. 22) to fresh reimbursement tailwinds in the U.K. and continued focus on Amvuttra (vutrisiran) as the company’s main growth engine. Nasdaq Below is a comprehensive roundup of the latest ALNY stock news, forecasts, and market-moving…
20 December 2025
·····
Alnylam Pharmaceuticals (ALNY) Stock After Hours: What Happened After the Dec. 19, 2025 Close — and What to Watch Before the Next Market Open

Alnylam Pharmaceuticals (ALNY) Stock After Hours: What Happened After the Dec. 19, 2025 Close — and What to Watch Before the Next Market Open

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) finished Friday, December 19, 2025, with shares around $400 and little change in after-hours trading — but the setup into the next U.S. session looks more eventful than the calm “after the bell” tape suggests. ALNY ended the day near $400.23 (up about 1.15%), after trading roughly between the mid-$395s and low-$408s on heavy volume…
20 December 2025
·····

Stock Market Today

  • Meta Platforms: A 'Magnificent Seven' Stock Up 577% in a Decade and Still Undervalued
    January 31, 2026, 4:33 PM EST. Meta Platforms (META) has surged 577% over the past decade despite facing scandals, fines, and criticism. The company reported a 24% revenue jump to $59.9 billion in its latest earnings, driven by AI-enhanced advertising tools aiding ad creation and targeting. Meta's operating income rose 6% to $24.7 billion, with a promising revenue growth outlook of 30% for the next quarter-the fastest in five years. Trading at a price-to-earnings ratio (P/E) of 25.4, Meta remains cheaper than the S&P 500 average P/E of 28.1 and significantly undervalued compared to its 'Magnificent Seven' tech peers. Despite rapid growth averaging 23% annually, markets continue to doubt its true worth, marking Meta as a compelling bargain in a competitive tech environment.
Go toTop